PI3K/HDAC-IN-3

PI3K/HDAC-IN-3 (36) is a PI3K and HDAC dual inhibitor, with IC50 values of 0.23 nM and 172 nM for PI3Kα and HDAC1, respectively. PI3K/HDAC-IN-3 (36) suppresses AKT phosphorylation and increased H3 acetylation in MV4-11 cells. PI3K/HDAC-IN-3 (36) exhibits significant and dose-dependent anticancer efficacy in a MV4-11 xenograft model[1].

Product Specifications

CAS Number

[3006905-22-9]

UNSPSC

12352005

Target

HDAC; PI3K

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pi3k-hdac-in-3.html

Solubility

10 mM in DMSO

Smiles

CC1=C2C(C(OCCCCCCC(NC3=C(C=CC=C3)N)=O)=CC(C4=CC(NS(C5=CC=C(F)C=C5F)(=O)=O)=C(OC)N=C4)=C2)=NC=N1

Molecular Formula

C34H34F2N6O5S

Molecular Weight

676.73

References & Citations

[1]Kehui Zhang, et al. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur J Med Chem. 2023 Nov 30:264:116015.